Marketing research of the national antiarrhythmic drugs market

• Main Authors: T. P. Zarichna, T. S. Raikova, T. S. Brytanova, Assani Doshi Rainna
• Format: Article
• Language: English
• Published: Zaporozhye State Medical University 2019-08-01
• Series: Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki
• Subjects: pharmaceutical preparations; pharmaceutical market; drug industry; competition
• Online Access: http://pharmed.zsmu.edu.ua/article/view/171073/172671

The purpose – marketing research of the national antiarrhythmic drugs market.Materials and methods. The State Register of Medicinal Products of Ukraine and Compendium-2019 were used as the research materials. Methods of system, marketing, statistical and content analysis. Results. The analysis of the range of antiarrhythmic drugs was conducted according to such criteria as composition, release form and originality. It showed the heterogeneity of this segment of Ukrainian pharmaceutical market. Thus, solid and liquid dosage forms, both original and generic could be found in the market. The analysis of the company structure of the studied market segment allowed to establish, that domestic pharmaceutical companies supply only 48 % of drugs (13 dosage forms) for this market segment, while foreign pharmaceutical companies prevail (52 %). In this connection, the development of new medicinal products of the specified activity and the mastering of their production on the territory of Ukraine is relevant. The calculated tension coefficient showed that the highest competition is observed among manufacturers of analog preparations containing amiodarone hydrochloride (Кvi = 0.93). Also, the specific weight of each of the manufacturers of antiarrhythmic drugs was calculated and it was established, that (LLC) Pharmaceutical Company Zdorovye has the largest share (dij = 0.1481).Conclusions. Conducted marketing studies of the range of the national antiarrhythmic drugs market showed the heterogeneity of this segment in terms of dosage forms and originality of drugs. The analysis of the company structure has established a high level of competition among the leading foreign pharmaceutical companies, whose share is 52 %. The coefficient of tension and the share of the segment, of each manufacturers of antiarrhythmic drugs, was calculated.